Advertisement
Advertisement
U.S. markets open in 1 hour 36 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Merck & Co., Inc. (MRK.BA)

Buenos Aires - Buenos Aires Delayed Price. Currency in ARS
Add to watchlist
3,927.00+77.50 (+2.01%)
At close: 04:56PM ART
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3,849.50
Open3,838.00
Bid3,900.00 x 0
Ask3,923.00 x 0
Day's Range3,838.00 - 3,974.00
52 Week Range2,390.50 - 3,999.00
Volume557
Avg. Volume1,608
Market Cap27.436T
Beta (5Y Monthly)0.46
PE Ratio (TTM)5,623.05
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield61.74 (1.66%)
Ex-Dividend DateMar 14, 2022
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for MRK.BA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Reuters

      Generic drugmakers to sell Pfizer's Paxlovid for $25 or less in low-income countries

      Several generic drugmakers that will produce versions of Pfizer's COVID-19 antiviral treatment Paxlovid have agreed to sell the medicine in low- and middle-income countries for $25 a course or less, the Clinton Health Access Initiative (CHAI) said on Thursday. CHAI said it could not disclose the names of the manufacturers who have agreed to the price ceiling, because they are still in the early stage of product development and have not received regulatory approval.

    • Reuters

      RPT-New class of cancer drugs down, not out, after Roche trial setback - analysts

      The fresh blow to Roche's hopes in a closely watched class of cancer immunotherapies cast a long shadow across the crowded field on Wednesday, but the latest setback is not the end of the road for these oncology treatments, analysts say. Roche said an interim analysis of an ongoing clinical trial showed that its experimental drug, tiragolumab, failed to meaningfully slow disease progression in newly diagnosed patients with advanced non-small-cell lung cancer (NSCLC) in combination with its approved PD-L1 immunotherapy Tecentriq, versus Tecentriq alone. The study will continue to evaluate whether the combination helps patients live longer, the gold standard for cancer treatments.

    • Reuters

      New class of cancer drugs down, not out, after Roche trial setback - analysts

      The fresh blow to Roche's hopes in a closely watched class of cancer immunotherapies cast a long shadow across the crowded field on Wednesday, but the latest setback is not the end of the road for these oncology treatments, analysts say. Roche said an interim analysis of an ongoing clinical trial showed that its experimental drug, tiragolumab, failed to meaningfully slow disease progression in newly diagnosed patients with advanced non-small-cell lung cancer (NSCLC) in combination with its approved PD-L1 immunotherapy Tecentriq, versus Tecentriq alone. The study will continue to evaluate whether the combination helps patients live longer, the gold standard for cancer treatments.

    Advertisement
    Advertisement